ERBB2 and breast cancer: Regarding the latter, a study published by Zhu et al. in 2018 demonstrates that the expression of miR-451, miR-222, and miR-20a during neoadjuvant treatment of breast cancer is associated with sensitivity to chemotherapy in the luminal subtype HER-2-negative [7].